Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
8
7
2022
Statut:
epublish
Résumé
We aimed to compare clinical severity of Omicron BA.4/BA.5 infection with BA.1 and earlier variant infections among laboratory-confirmed SARS-CoV-2 cases in the Western Cape, South Africa, using timing of infection to infer the lineage/variant causing infection. We included public sector patients aged ≥20 years with laboratory-confirmed COVID-19 between 1-21 May 2022 (BA.4/BA.5 wave) and equivalent prior wave periods. We compared the risk between waves of (i) death and (ii) severe hospitalization/death (all within 21 days of diagnosis) using Cox regression adjusted for demographics, comorbidities, admission pressure, vaccination and prior infection. Among 3,793 patients from the BA.4/BA.5 wave and 190,836 patients from previous waves the risk of severe hospitalization/death was similar in the BA.4/BA.5 and BA.1 waves (adjusted hazard ratio [aHR] 1.12; 95% confidence interval [CI] 0.93; 1.34). Both Omicron waves had lower risk of severe outcomes than previous waves. Prior infection (aHR 0.29, 95% CI 0.24; 0.36) and vaccination (aHR 0.17; 95% CI 0.07; 0.40 for boosted vs. no vaccine) were protective. Disease severity was similar amongst diagnosed COVID-19 cases in the BA.4/BA.5 and BA.1 periods in the context of growing immunity against SARS-CoV-2 due to prior infection and vaccination, both of which were strongly protective.
Identifiants
pubmed: 35794899
doi: 10.1101/2022.06.28.22276983
pmc: PMC9258293
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Bill & Melinda Gates Foundation
ID : INV-017293
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD080465
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Trop Med Int Health. 2022 Jun;27(6):564-573
pubmed: 35411997
Int J Infect Dis. 2022 May;118:150-154
pubmed: 35235826
Nature. 2022 Apr;604(7906):553-556
pubmed: 35240676
Emerg Infect Dis. 2022 Sep;28(9):1856-1858
pubmed: 35914518
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
N Engl J Med. 2022 Apr 7;386(14):1314-1326
pubmed: 35196424
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Int J Popul Data Sci. 2019 Nov 20;4(2):1143
pubmed: 32935043
Sci Transl Med. 2022 Aug 24;14(659):eabo7081
pubmed: 35638937
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Nature. 2022 Jun;606(7916):848-849
pubmed: 35750920
Nat Med. 2022 Sep;28(9):1933-1943
pubmed: 35675841